ArticleKorean circulation journal2026
Temporal Trend of Cardiovascular Disease Burden Among Cancer Patients Between 2005 and 2022: Nationwide Population-Based Cohort Study in South Korea.
Article in Korean circulation journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Cancer Survival Improves, the Heart Becomes the Next Frontier.Korean circulation journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
BACKGROUND AND
objectivesComprehensive data on the changing landscape of cardiovascular disease (CVD) burden in cancer patients remains limited. We aimed to analyze the temporal trend in the burden of CVD among cancer patients.
methodsUsing a nationwide administrative claims database in Korea, we analyzed 1,322,502 adults (aged ≥18) newly diagnosed with cancer (2005-2022). The primary outcomes were: 1) temporal trends in CVD incidence, including ischemic heart disease (IHD), heart failure (HF), and stroke; and 2) cause-specific mortality trends, focusing on cancer and CVD-related deaths. Both crude and age-standardized rates were calculated for CVD incidence and mortality.
resultsThe 1-year age-standardized cancer mortality rate showed a substantial decline from 134.0 to 76.3 per 1,000 person-years. While the age-standardized 1-year CVD incidence initially decreased from 91.7 to 50.6 per 1,000 person-years (2005-2014), this improvement plateaued and showed an upward trend thereafter. Analysis of CVD subtypes revealed divergent patterns: age-standardized IHD incidence declined, while HF incidence rose by 136%, 52%, and 37% at 1-, 3-, and 5-year follow-ups. Despite improvements in cancer mortality, the proportion of deaths attributed to CVD increased from 1.0% to 1.5% at 1-year, corresponding to a 50% relative rise and showed a similar upward trend at 5-year follow-up, with HF emerging as an increasingly cause of cardiovascular death (increasing from 10.8% to 26.3% of CVD mortality).
conclusionsWhile cancer-specific mortality has improved significantly, cardiovascular mortality remains a growing concern, due to the increasing burden of HF in cancer patients. Ongoing CVD pattern surveillance in cancer patients is crucial for targeted interventions and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.